C-reactive protein and cardiovascular outcomes in smokers versus nonsmokers in non-ST-elevation acute coronary syndrome (from the TACTICS-TIMI 18 trial).
We investigated the role of inflammation, as measured by high-sensitivity C-reactive protein (CRP) levels, in cardiovascular risk in smokers who have acute coronary syndrome. Despite fewer traditional risk factors, smokers who had acute coronary syndrome had higher CRP levels than did nonsmokers (7.0 vs 5.1 mg/L, p <0.001). CRP was associated with adverse cardiovascular outcomes in smokers and nonsmokers, even when adjusted for the presence of pulmonary disease.
Moghbeli
Nazanin
N
Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Kirtane
Ajay J
AJ
Ray
Kausik K
KK
Murphy
Sabina A
SA
Gibson
C Michael
CM
Braunwald
Eugene
E
Cannon
Christopher P
CP
D000789:Angina, Unstable / Q000097:blood* / Q000453:epidemiology / Q000503:physiopathology; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism*; D004562:Electrocardiography; D006801:Humans; D008171:Lung Diseases / Q000097:blood / Q000209:etiology; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000453:epidemiology / Q000503:physiopathology; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D012720:Severity of Illness Index; D012907:Smoking / Q000009:adverse effects / Q000097:blood*; D015996:Survival Rate; D013577:Syndrome
D015415:Biomarkers; D002097:C-Reactive Protein